Posted by Michael Wonder on 18 Sep 2024
The ICER developing special report for submission to CMS as part of public comment process on Medicare drug price negotiations
18 September 2024 - Report to reflect legislative specifications in the Inflation Reduction Act and subsequent CMS guidance regarding price negotiations.
The ICER announced today that it will develop a special report for CMS on two therapies in high demand for treating chronic obstructive pulmonary disease. The ICER will evaluate Breo Ellipta and Trelegy Ellipta (both from GSK). This report will be submitted to CMS as part of the 2025 public comment process defined in CMS guidance on Medicare Drug Price Negotiations for price applicability year 2027.
